Table 2.
Baseline characteristics of participating study populations
| Mean age, years (sd) | Female, % | Black, % | CVD, % | DM, % | Smoking, % | Hypertension, % | Hypercholesterolemia, % | Median ACR/PCR, mg/g | Mean eGFR ml/min/1.73m2 (sd) | |
|---|---|---|---|---|---|---|---|---|---|---|
|
Studies with Albumin:Creatinine Ratio
| ||||||||||
| British Columbia | 68.5 (13.9) | 44.8 | 0.5 | 23.5 | 32.4 | 5.4 | 41.1 | -- | 94.6 | 34.9 (17.9) |
| CRIB | 61.7 (14.2) | 34.1 | 5.8 | 45.5 | 17.2 | 13.3 | 90.6 | -- | 467.2 | 22.2 (10.6) |
| Grampian-ACR | 73.0 (11.4) | 56.4 | 0 | 24.2 | 8.5 | 61.6 | 59.5 | -- | 26.5 | 34.6 (5.8) |
| MASTERPLAN | 60.5 (12.4) | 31.0 | 2.7 | 30.2 | 24.3 | 20.2 | 95.4 | 18 | 119.1 | 36.3 (13.2) |
| NephroTest | 59.6 (15.0) | 31.7 | 9.6 | 16.0 | 26.0 | 10.0 | 88.7 | 16.6 | 77.6 | 41.1 (20.1) |
| RENAAL | 60.2 (7.4) | 36.8 | 15.2 | 35.0 | 100 | 18.1 | 96.4 | -- | 1245.5 | 39.8 (12.3) |
| Steno | 42.6 (10.8) | 38.1 | 0 | 10.2 | 100 | 51.9 | 82.2 | 36.9 | 498.0 | 69.8 (27.5) |
|
| ||||||||||
|
Studies with Protein:Creatinine Ratio
| ||||||||||
| AASK | 54.6 (10.7) | 38.8 | 100.0 | 51.6 | 0 | 29.3 | 100 | 55.6 | 80.8 | 42.5 (13.2) |
| Grampian-PCR | 73.4 (14.8) | 61.6 | 0 | 17.0 | 2.5 | 55.4 | 52.8 | -- | 300.9 | 34.6 (6.2) |
| MDRD | 51.7 (12.4) | 39.5 | 7.9 | 9.6 | 5.1 | 16.6 | 86.2 | 23.0 | 268.5 | 32.6 (12.3) |
| MMKD | 46.4 (12.3) | 34.0 | 0 | 12.3 | 0 | 21.7 | 89.2 | 38.4 | 1035.0 | 43.4 (26.7) |
| REIN | 49.5 (13.6) | 23.6 | 0.6 | 0 | 7.7 | 18.2 | 86.4 | -- | 2337.4 | 42.9 (18.5) |
| REIN 2 | 54.2 (15.0) | 25.1 | 0 | 0 | 5.1 | 16.1 | 73.1 | -- | 1875.3 | 31.0 (16.7) |
|
| ||||||||||
|
Studies with Dipstick Proteinuria
| ||||||||||
| Kaiser Permanente Northwest | 71.79(9.73) | 56.0 | 3.1 | 44.8 | 38.8 | 12.8 | 92.9 | 26.0 | -- | 45.7 (10.5) |
†
per 1,000 person-years; AASK: African American Study of Kidney Disease and Hypertension; CRIB: Chronic Renal Impairment in Birmingham; MASTERPLAN: Multifactorial Approach and Superior Treatment Efficacy in Renal Patients with the Aid of a Nurse Practicioner; MDRD: Modification of Diet in Renal Disease; MMKD: Mild to Moderate Kidney Disease Study; REIN: Ramipril Efficacy in Nephropathy; REIN 2: Ramipril Efficacy in Nephropathy 2; RENAAL: Reduction of Endpoints in Non-insulin Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan; Steno: Steno Type 1 Diabetes Study